PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23232926-6	2013	However, pretreatment with EGF receptor blockers AG1478 or DAPH, but not with a phosphatidylinositol-3 kinase inhibitor LY294002 or an Akt1/2 kinase inhibitor Akt inhibitor VIII, attenuated 3",4"-dimethoxythioflavone-induced vasorelaxation.	4,5-dianilinophthalimide	59-63	epidermal growth factor receptor	Rattus norvegicus	27-39	
24028616-8	2013	However, pretreatment with EGF receptor blockers, AG1478 or DAPH, resulted in attenuated G1-induced vasorelaxation.	4,5-dianilinophthalimide	60-64	epidermal growth factor receptor	Rattus norvegicus	27-39	
11479217-1	2001	Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2.	4,5-dianilinophthalimide	183-209	epidermal growth factor receptor	Rattus norvegicus	22-34	
11751714-6	2001	The EGFR tyrosine kinase-specific inhibitors 4,5-dianilinophthalimide (10 micromol/L) and AG1478 (250 nmol/L) reduced contraction in aorta from DOCA-salt by 85+/-14% and 65+/-10%, respectively.	4,5-dianilinophthalimide	45-69	epidermal growth factor receptor	Rattus norvegicus	4-8	
11479217-1	2001	Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2.	4,5-dianilinophthalimide	183-209	epidermal growth factor receptor	Rattus norvegicus	36-40	
11479217-1	2001	Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2.	4,5-dianilinophthalimide	210-215	epidermal growth factor receptor	Rattus norvegicus	22-34	
11479217-1	2001	Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2.	4,5-dianilinophthalimide	210-215	epidermal growth factor receptor	Rattus norvegicus	36-40